Compare Beyond Meat Inc (BYND) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Summit Therapeutics Inc — how do they compare? Beyond Meat Inc trades at $0.41 (market cap $215.41M), while Summit Therapeutics Inc trades at $15.16 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 56× Beyond Meat Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Beyond Meat Inc nearer its low. Which is the better fit depends on your goals.
| BYND | SMMT | |
|---|---|---|
Market Cap | $215.41M | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $3.62 | $26.98 |
52-Week Low | $0.41 | $12.55 |
Enterprise Value | $455.69M | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Beyond Meat (BYND) trades at $0.4066, down 21.81% amid a 1-for-30 reverse stock split announcement. The stock is technically bearish with negative cash flow from operations, though recent quarters show mixed earnings beats. Revenue has declined from $419M in 2022 to $275M in 2025, but net income turned positive at $178M in 2025, driven by a one-time gain. Analyst sentiment is heavily skewed toward sell ratings, reflecting skepticism about the company's turnaround efforts and persistent cash burn.
The outlook remains challenging due to declining sales, high cash burn, and weak investor confidence. While valuation ratios like P/S of 0.61 appear low, the risk of further dilution or delisting outweighs potential upside. Key risks include execution missteps and competitive pressure in the plant-based food sector.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
